Ever since German chemist Anton Köllisch synthesized it in 1912, to control abnormal bleeding, 3, 4-methylenedioxy-methamphetamine or MDMA has come a long way. Commonly abused in dance parties, concerts and music festivals since 1970-80s, MDMA is now classified as a Schedule I substance due to its high potential for abuse with no medicinal use. The drug, also popularly known as Molly or ecstasy is categorized as a hallucinogen along with LSD and other drugs. The 2016 annual survey of National Institute on Drug Abuse (NIDA) on teen drug use reported that 2.7 percent of 12th graders, 1.8 percent of 10th graders, and one percent of 8th graders were past year MDMA users with males living in the city being the highest consumers.
The ‘club drug’ MDMA produces energizing effects that are similar to the stimulants amphetamines, and psychedelic effects similar to hallucinogens. MDMA is illegal in most countries but its use in America has been legalized for clinical trial purposes to treat terminally ill patients. Researchers are continuing to investigate into the highly addictive drug’s possible medical benefits for patients suffering from post-traumatic-stress-disorder (PTSD).
Advances in research on psychedelic drugs to improve mental health
A few pioneering studies are investigating the use of psychedelic drugs like LSD, magic mushrooms and MDMA in treating mental disorders like anxiety and PTSD concluding that these drugs could have a beneficial role in providing relief from the symptoms. According to them, LSD could help with anxiety and psilocybin, the active ingredient in magic mushrooms, could treat alcoholism.
There are at least seven such studies being currently investigated to determine the efficacy of MDMA in treating mental disorders, including a study probing into its effect on terminal cancer patients with not many months left to live. Researchers believe that continued medical research into psychedelic drugs could benefit mentally ill patients who have not yet shown improvement with currently available treatments.
Anonymous Bitcoin investor donates millions for MDMA research
Surprisingly, an anonymous Bitcoin investor,— believing MDMA-assisted psychotherapy has shown great promise—has discreetly donated $4 million to finance research on the potential uses of the famous rave drug in treating PTSD. The Pineapple Fund founded by the unnamed ‘cryptocurrency philanthropist’, has transferred the pledged amount to a non-profit called the Multidisciplinary Association for Psychedelic Studies (MAPS).
Rick Doblin, founder and executive director of MAPS, says that the fund’s financial support “is a dream come true” in the absence of funding from government agencies or major medical research foundations. He is hopeful that once MDMA-assisted psychotherapy for PTSD is made legally available, it “will indeed be a gift to the world from the psychedelic science and cryptocurrency communities.”
PTSD is a severe mental condition that occurs from emotional trauma, especially among military veterans and sexual assault survivors. The disorder impairs a person’s ability to function in social and family settings giving rise to occupational instability, marital and family discord, loss of productivity and difficulties in parenting.
Early treatment is important
PTSD can be treated with various psychotherapies, medications and experiential treatments like yoga and meditation. Early treatment is important as it can help to reduce the symptoms and provide peace and relief to the patient.
If you or your loved one is suffering from any mental health problem, contact the California Mental Health Helpline for information on some of the most reputed mental health centers in California that offer comprehensive therapeutic recovery programs. Call us at our 24/7 helpline 855-559-3923 or chat online with one of the specialists to get advice on the best mental health treatment centers in California.